Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font

Welcome to Robins Social Network

Be part of the community and join us today!

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.


To order this 350+ page report, which features 150+ figures and 200+ tables, please visit thislink


The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

§  Type of Tumor Marker

  • ctDNA
  • cfDNA
  • CTCs
  • Exosomes
  • Others


§  Application

  • Diagnosis / Early Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring


§  Target Cancer Indication

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Gastric Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others


§  End Users

  • Hospitals
  • Research Institutes
  • Others


§  Key Geographical Regions 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World


The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkersreport features the following companies, which we identified to be key players in this domain:

§  Amoy Diagnostics

§  DiaCarta

§  HaploX Biotechnology

§  NeoGenomics


§  Swift Biosciences

§  Sysmex Inostics

§  Thermo Fisher Scientific

Press Release: Variation 3 (Format 4)


Table of Contents


1. Preface

2. Executive Summary

3. Introduction


4. Non-Invasive Cancer Screening and Diagnosis

5. Market Landscape


6. Company Profiles

7. Partnerships and Collaborations


8. Funding and Investment Analysis

9. Liquid Biopsy: Initiatives of Big Pharma Players

10. Key Acquisition Targets


11. Other Non-Invasive Cancer Diagnostics

12. Market Sizing and Opportunity Analysis

13. Survey Insights


14. Conclusion

15. Executive Insights


16. Appendix 1: Tabulated Data


17. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

on January 28 at 8:36

Comments (0)

Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2022 Content By Members. All Rights Reserved.